Keyword: ARCH Venture Partners
Glympse Bio, a startup that builds bioengineered in vivo sensors for disease, has emerged from stealth with a $22 million series A round.
The appointment puts the Sage and Voyager co-founder in charge of advancing a muscarinic agonist he worked on at Eli Lilly in the 1990s.
Mindstrong Health rounded up $15 million in series B financing to continue development of its mental health-tracking smartphone app.
Alta Partners raised $130 million for its ninth venture capital fund, focusing on biotech and healthcare technology companies.
Metacrine raised $65 million to launch phase 1 testing of its FXR agonist in NASH and gastrointestinal diseases later this month.
Brii Biosciences' mission is to overcome the challenges that have prevented the spread of innovative medicines throughout China.
Daphne Koller, an ex-Calico AI expert, plans to enlist data and machine learning to address shortcomings in drug discovery and development.
Accelerator has landed an $89.5 million federal contract to explore use of its investigational migraine drug to counteract nerve agents.
Hitting the IPO target would bring the preclinical anti-aging startup’s fundraising haul up toward $300 million.
The new funding will propel Unity Biotechnology's osteoarthritis asset into its first clinical trial.